These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 30253737)

  • 1. Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma.
    Lindenblatt D; Terraneo N; Pellegrini G; Cohrs S; Spycher PR; Vukovic D; Béhé M; Schibli R; Grünberg J
    BMC Cancer; 2018 Sep; 18(1):922. PubMed ID: 30253737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.
    Grünberg J; Lindenblatt D; Dorrer H; Cohrs S; Zhernosekov K; Köster U; Türler A; Fischer E; Schibli R
    Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1907-15. PubMed ID: 24859811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model.
    Lindenblatt D; Fischer E; Cohrs S; Schibli R; Grünberg J
    EJNMMI Res; 2014 Dec; 4(1):54. PubMed ID: 26116117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L1-CAM-targeted antibody therapy and (177)Lu-radioimmunotherapy of disseminated ovarian cancer.
    Fischer E; Grünberg J; Cohrs S; Hohn A; Waldner-Knogler K; Jeger S; Zimmermann K; Novak-Hofer I; Schibli R
    Int J Cancer; 2012 Jun; 130(11):2715-21. PubMed ID: 21796623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from (177)Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts.
    Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27196891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta emitters rhenium-188 and lutetium-177 are equally effective in radioimmunotherapy of HPV-positive experimental cervical cancer.
    Phaeton R; Jiang Z; Revskaya E; Fisher DR; Goldberg GL; Dadachova E
    Cancer Med; 2016 Jan; 5(1):9-16. PubMed ID: 26625938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioimmunotherapy of PANC-1 Human Pancreatic Cancer Xenografts in NRG Mice with Panitumumab Modified with Metal-Chelating Polymers Complexed to
    Aghevlian S; Cai Z; Lu Y; Hedley DW; Winnik MA; Reilly RM
    Mol Pharm; 2019 Feb; 16(2):768-778. PubMed ID: 30589553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
    Weber T; Bötticher B; Mier W; Sauter M; Krämer S; Leotta K; Keller A; Schlegelmilch A; Grosse-Hovest L; Jäger D; Haberkorn U; Arndt MA; Krauss J
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):489-98. PubMed ID: 26341366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of
    Repetto-Llamazares AHV; Malenge MM; O'Shea A; Eiríksdóttir B; Stokke T; Larsen RH; Dahle J
    Eur J Haematol; 2018 Oct; 101(4):522-531. PubMed ID: 29993152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo evaluation of 177Lu- and 67/64Cu-labeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumors.
    Grünberg J; Novak-Hofer I; Honer M; Zimmermann K; Knogler K; Bläuenstein P; Ametamey S; Maecke HR; Schubiger PA
    Clin Cancer Res; 2005 Jul; 11(14):5112-20. PubMed ID: 16033825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma Model.
    Song IH; Jeong MS; Hong HJ; Shin JI; Park YS; Woo SK; Moon BS; Kim KI; Lee YJ; Kang JH; Lee TS
    Clin Cancer Res; 2019 Oct; 25(20):6148-6159. PubMed ID: 31337646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
    Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
    Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
    Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
    J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis.
    Knogler K; Grünberg J; Zimmermann K; Cohrs S; Honer M; Ametamey S; Altevogt P; Fogel M; Schubiger PA; Novak-Hofer I
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):603-11. PubMed ID: 17255283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of 177Lu-DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties.
    Knogler K; Grünberg J; Novak-Hofer I; Zimmermann K; Schubiger PA
    Nucl Med Biol; 2006 Oct; 33(7):883-9. PubMed ID: 17045168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer.
    Behe M; Alt K; Deininger F; Bühler P; Wetterauer U; Weber WA; Elsässer-Beile U; Wolf P
    In Vivo; 2011; 25(1):55-9. PubMed ID: 21282735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model.
    Weber T; Bötticher B; Arndt MA; Mier W; Sauter M; Exner E; Keller A; Krämer S; Leotta K; Wischnjow A; Grosse-Hovest L; Strumberg D; Jäger D; Gröne HJ; Haberkorn U; Brem G; Krauss J
    Cancer Lett; 2016 Oct; 381(2):296-304. PubMed ID: 27524505
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.